详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Targeting YAP suppresses ovarian cancer progression through regulation of the PI3K/Akt/mTOR pathway

90| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Obstet & Gynecol, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China [2]Wuhan First Hosp, Dept Obstet & Gynecol, Wuhan 430030, Hubei, Peoples R China [3]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Thorac Surg, Wuhan 430030, Hubei, Peoples R China

出处：

DOI：

ISSN：

关键词： ovarian cancer Yes-associated protein phosphoinositide 3-kinase/Akt/mammalian target of rapamycin peptide 17

摘要：

Ovarian cancer (OC) is highly metastatic due to frequent peritoneal dissemination, and its treatment poses a major challenge in clinical practice. Yes-associated protein (YAP) is known to be associated with the development of multiple tumors. However, whether targeting YAP can restrain OC progression and the underlying mechanisms have yet to be fully elucidated. In the present study, YAP was found to be highly expressed in OC, and its expression was correlated with the prognosis of OC patients. Moreover, silencing of YAP markedly inhibited the malignant behavior of OC cells, possibly through regulation of the PI3K/Akt/mTOR pathway. Notably, peptide 17, a YAP inhibitor, exerted a significant attenuating effect on OC progression by diminishing the activation of the PI3K/Akt/mTOR pathway in vitro as well as in vivo. Taken together, these findings demonstrated that targeting YAP attenuated OC progression and suggested the potential application of peptide 17 in OC therapy, thus providing new insights into improving the treatment of OC.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2018]版：

大类 | 3 区医学

小类 | 4 区肿瘤学

最新[2025]版：

大类 | 3 区医学

小类 | 4 区肿瘤学

JCR分区：

出版当年[2017]版：

Q3 ONCOLOGY

最新[2024]版：

Q2 ONCOLOGY

影响因子： 3.9 最新[2024版] 3.5 最新五年平均 2.976 出版当年[2017版] 2.804 出版当年五年平均 2.662 出版前一年[2016版] 3.041 出版后一年[2018版]

第一作者：

第一作者单位： [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Obstet & Gynecol, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Elevated expression of yes-associated protein is associated with the malignant status and prognosis of laryngeal squamous cell carcinoma [2]ß-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma [3]Involvement of Yes-associated protein 1 in inflammation-induced benign prostatic hyperplasia [4]Proliferation and differentiation of rat adipose-derived stem cells are regulated by yes-associated protein [5]Yes相关蛋白通过Wnt/β-catenin信号通路调控软骨细胞Sox9表达的研究 [6]Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans [7]Sulfatase 2 (SULF2) Monoclonal Antibody 5D5 Suppresses Human Cholangiocarcinoma Xenograft Growth Through Regulation of a SULF2-Platelet-Derived Growth Factor Receptor Beta-Yes-Associated Protein Signaling Axis [8]YAP1 Recognizes Inflammatory and Mechanical Cues to Exacerbate Benign Prostatic Hyperplasia via Promoting Cell Survival and Fibrosis [9]Taurocholate Induces Connective Tissue Growth Factor Expression in Hepatocytes Through ERK-YAP Signaling [10]PDE4D binds and interacts with YAP to cooperatively promote HCC